UT09 Vaccine for treatment of obesity, NAFLD and Hypertriglyceridemia
Composition of Matter Patent for UT09 approved by USPTO - 23 Dec 2025
Immunotherapeutic Composition for Prevention of Obesity, Nonalcoholic Fatty Liver Disease and Hypertriglyceridemia, and Methods of use and preparation thereof
Notice of Allowance for another key patent:
UT09 Vaccine for treatment of obesity, NAFLD and Hypertriglyceridemia
Recognized as a
Global Breakthrough in Metabolic Innovation
Utopia Therapeutics was recognized among the Top 5 Innovations at BioAsia 2025, with widespread acclaim in media and scientific communities gaining attention from health innovators, researchers, and policy leaders worldwide.
Follow our journey as we move toward first-in-human trials.